Epidemiology of capsular and surface polysaccharide in Staphylococcus aureus infections complicated by bacteraemia

被引:36
作者
Roghmann, M
Taylor, KL
Gupte, A
Zhan, M
Johnson, JA
Cross, A
Edelman, R
Fattom, AI
机构
[1] VA Maryland Hlth Care Syst, Med Care Clin Ctr, Epidemiol Sect, Baltimore, MD USA
[2] VA Maryland Hlth Care Syst, Pathol & Lab Med Serv, Baltimore, MD USA
[3] Nabi Biopharmaceut, Rockville, MD USA
[4] Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA
[5] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA
[6] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA
[7] Univ Maryland, Sch Med, Dept Med, Div Geog Med, Baltimore, MD 21201 USA
关键词
Staphylococcus aureus; bacteraemia; capsular serotyping; methicillin resistance; immunotherapy;
D O I
10.1016/j.jhin.2004.07.014
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Staphylococcus aureus is a leading cause of serious hospital and community-acquired infections. The discovery of serologically distinct capsular polysaccharides on the surface of clinical isolates has allowed the development of vaccines and passive protective immunity. We have studied patient characteristics, infection characteristics and the surface and capsular polysaccharide serotype distribution in patients with S. aureus infections complicated by bacteraemia admitted to VA hospitals in Maryland between 1995 and 2000. Nine hundred and ninety-three blood cultures from 331 patients were positive for S. aureus. Thirty-eight percent of patients had diabetes, 11% had end-stage renal failure, and 23% were injection drug users. Forty-two percent of infections were caused by methicillin-resistant strains (MRSA), and 60% were acquired during hospitalization. Serotyping of the first available isolate per patient (N=234 isolates) using polyclonal antibodies showed three major phenotypes-42%, type 8 (T8) capsule; 50%, type 5 (T5) capsule; and 8%, 336 polysaccharide. MRSA isolates were significantly more likely to be T5 than methicillin-susceptible isolates (66% vs. 39%, P < 0.001). The proportion of T5 MRSA increased significantly (years 1-2: 41%; years 3-4: 65%; years 5-6: 90%, P < 0.001). This large sample of patients with serious S. aureus infection confirms that capsular polysaccharides T5 and T8 cause most human infections, and together with serotype 336, account for nearly all those with bacteraemia. (C) 2004 The Hospital Infection Society. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:27 / 32
页数:6
相关论文
共 15 条
  • [1] PREDOMINANCE OF 2 NEWLY DESCRIBED CAPSULAR POLYSACCHARIDE TYPES AMONG CLINICAL ISOLATES OF STAPHYLOCOCCUS-AUREUS
    ARBEIT, RD
    KARAKAWA, WW
    VANN, WF
    ROBBINS, JB
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1984, 2 (02) : 85 - 91
  • [2] Molecular, antibiogram and serological typing of Staphylococcus aureus isolates recovered from Al-Makased hospital in East Jerusalem
    Essawi, T
    Na'was, T
    Hawwari, A
    Wadi, S
    Doudin, A
    Fattom, AI
    [J]. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 1998, 3 (07) : 576 - 583
  • [3] SYNTHESIS AND IMMUNOLOGICAL PROPERTIES IN MICE OF VACCINES COMPOSED OF STAPHYLOCOCCUS-AUREUS TYPE-5 AND TYPE-8 CAPSULAR POLYSACCHARIDES CONJUGATED TO PSEUDOMONAS-AERUGINOSA EXOTOXIN-A
    FATTOM, A
    SCHNEERSON, R
    SZU, SC
    VANN, WF
    SHILOACH, J
    KARAKAWA, WW
    ROBBINS, JB
    [J]. INFECTION AND IMMUNITY, 1990, 58 (07) : 2367 - 2374
  • [4] LABORATORY AND CLINICAL-EVALUATION OF CONJUGATE VACCINES COMPOSED OF STAPHYLOCOCCUS-AUREUS TYPE-5 AND TYPE-8 CAPSULAR POLYSACCHARIDES BOUND TO PSEUDOMONAS-AERUGINOSA RECOMBINANT EXOPROTEIN-A
    FATTOM, A
    SCHNEERSON, R
    WATSON, DC
    KARAKAWA, WW
    FITZGERALD, D
    PASTAN, I
    LI, XR
    SHILOACH, J
    BRYLA, DA
    ROBBINS, JB
    [J]. INFECTION AND IMMUNITY, 1993, 61 (03) : 1023 - 1032
  • [5] A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge
    Fattom, AI
    Sarwar, J
    Ortiz, A
    Naso, R
    [J]. INFECTION AND IMMUNITY, 1996, 64 (05) : 1659 - 1665
  • [6] PREDOMINANCE OF CAPSULAR POLYSACCHARIDE TYPE-5 AMONG OXACILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS
    FOURNIER, JM
    BOUVET, A
    BOUTONNIER, A
    AUDURIER, A
    GOLDSTEIN, F
    PIERRE, J
    BURE, A
    LEBRUN, L
    HOCHKEPPEL, HK
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1987, 25 (10) : 1932 - 1933
  • [7] CDC DEFINITIONS FOR NOSOCOMIAL INFECTIONS, 1988
    GARNER, JS
    JARVIS, WR
    EMORI, TG
    HORAN, TC
    HUGHES, JM
    [J]. AMERICAN JOURNAL OF INFECTION CONTROL, 1988, 16 (03) : 128 - 140
  • [8] National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992-April 2000, issued June 2000
    Gerberding, J
    Gaynes, R
    Horan, T
    Alonso-Echanove, J
    Edwards, J
    Emori, G
    Fridkin, S
    Hageman, J
    Henderson, T
    Lawton, R
    Peavy, G
    Richards, C
    Tolson, J
    Wages, J
    [J]. AMERICAN JOURNAL OF INFECTION CONTROL, 2000, 28 (06) : 429 - 448
  • [9] Guidry A, 1998, AM J VET RES, V59, P1537
  • [10] SEROTYPING AND ELECTRON-MICROSCOPY STUDIES OF STAPHYLOCOCCUS-AUREUS CLINICAL ISOLATES WITH MONOCLONAL-ANTIBODIES TO CAPSULAR POLYSACCHARIDE TYPE-5 AND TYPE-8
    HOCHKEPPEL, HK
    BRAUN, DG
    VISCHER, W
    IMM, A
    SUTTER, S
    STAEUBLI, U
    GUGGENHEIM, R
    KAPLAN, EL
    BOUTONNIER, A
    FOURNIER, JM
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1987, 25 (03) : 526 - 530